e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ResMed Inc. Common Stock (NY:RMD)

251.54 +0.62 (+0.25%)

Streaming Delayed Price Updated: 11:32 AM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Earnings Outlook For ResMed ↗

April 27, 2022

ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that ResMed will report an...

Via Benzinga

What 5 Analyst Ratings Have To Say About ResMed ↗

April 06, 2022

ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗

April 06, 2022

Upgrades

Via Benzinga

Expert Ratings For ResMed ↗

January 31, 2022

ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:

Via Benzinga

Recap: ResMed Q2 Earnings ↗

January 27, 2022

ResMed (NYSE:RMD) reported its Q2 earnings results on Thursday, January 27, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings ResMed missed...

Via Benzinga

Ten Healthcare Companies With High Payout Ratio ↗

March 25, 2022

The healthcare industry is among the biggest U.S. market segments in terms of market capitalization, but when it comes to dividend payouts, they rank very low.

Via Talk Markets

3 Top S&P 500 Stock Market Gainers Today: Energy Dominates As Adobe Dives ↗

March 23, 2022

Energy and commodity plays were top performers Wednesday.

Via Investor's Business Daily

Markets Fall Amid Rising Oil Prices ↗

March 23, 2022

U.S. indices finished lower Wednesday as investors continue to weigh the Federal Reserve tapering outlook, inflation concerns and the Russia-Ukraine war. Oil prices have also...

Via Benzinga

3 Beaten-Down Growth Stocks With More Than 50% Upside Potential ↗

February 25, 2022

The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions.

Via InvestorPlace

Ominous Death Cross Forms On ResMed's Chart ↗

February 02, 2022

If history is any guide, there may be trouble ahead for shares of ResMed (NYSE:RMD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...

Via Benzinga

Earnings Scheduled For January 27, 2022 ↗

January 27, 2022

Companies Reporting Before The Bell • SAP (NYSE:SAP) is estimated to report quarterly earnings at $1.87 per share on revenue of $9.10 billion. •...

Via Benzinga

Sleep Apnea Device Maker Resmed Sees Improved Relative Strength ↗

January 14, 2022

Resmed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

ResMed's Return on Invested Capital Overview ↗

January 28, 2022

According to Benzinga Pro, during Q2, ResMed (NYSE:RMD) earned $201.75 million, a 0.91% increase from the preceding quarter. ResMed's sales decreased to $894.87 million, a 1.01%...

Via Benzinga

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron ↗

January 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

ResMed Q2 Earnings Highlights: Supply Chain Constraints, Unlimited Demand Due To Competitor Recall ↗

January 28, 2022

ResMed Inc (NYSE: RMD) revealed a 13% Y/Y jump in Q2 FY22 revenue to $894.9 million, missing the consensus of $935.25 million. The growth was below analyst expectations...

Via Benzinga

The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study ↗

January 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Preview: ResMed ↗

January 26, 2022

ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-01-27. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More ↗

January 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...

Via Benzinga

This Company Just Made a Possibly Lucrative Acquisition — What's Next? ↗

January 14, 2022

Photo by Ccfb on Pixabay This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The global...

Via Benzinga

What 4 Analyst Ratings Have To Say About ResMed ↗

January 13, 2022

Within the last quarter, ResMed (NYSE:RMD) has observed the following analyst ...

Via Benzinga

Take Action To Unlock Supply Chain Disruption Issues ↗

January 07, 2022

Businesses are grappling with supply chain disruption. And beating this challenge requires leaders to take decisive action right now.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For January 13, 2022 ↗

January 13, 2022

Upgrades According to Morgan Stanley, the prior rating for SunPower Corp (NASDAQ:

Via Benzinga

4 Low-Beta Stocks To Buy For A Volatile Market ↗

December 08, 2021

Global economic uncertainty, inflationary pressure, a disappointing jobs report, and concerns around the COVID-19 Omicron variant are fostering market volatility. So, against this backdrop, we think it...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021 ↗

December 06, 2021

Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX:

Via Benzinga

Notable Resmed Insider Trades $2.9M In Company Stock ↗

November 16, 2021

Robert Douglas President And Chief Operating Officer, Resmed Inc., COO at Resmed (NYSE:RMD), made a large buy and sell of company shares on November 15, according to a new SEC...

Via Benzinga

CNBC's Final Trades: Fiserv, ResMed, Monster Beverage And This Semiconductor Company ↗

November 16, 2021

On CNBC’s “Halftime Report Fina...

Via Benzinga

Global Home Medical Equipment Market Size Is Estimated To Reach $56 Billion By 2027

November 09, 2021

Palm Beach, FL – November 9, 2021 – FinancialNewsMedia.com News Commentary – Over the last few years, and with the ‘help’ of the pandemic, home health care medical equipment industry has surged. Home...

Via FinancialNewsMedia

ResMed (RMD) Q1 2022 Earnings Call Transcript ↗

October 29, 2021

RMD earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs ↗

October 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc...

Via Benzinga

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗

October 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy